vertex presentation jp morgan, page-10

I take your points and agree about diversification, but Biota must also not drop the ball on their bread and butter (on what they understand best).

2012 should bring a nice injection of funds, so I believe FLUNET development should never stand still - neither should HRV or RSV.

"Too much patent overlap with Lani is a good reason to delay Flunet"

At the moment we are about to face 2-3 years patent underlap between Relenza and LANI, courtesy of poor planning.

Okay, we know LANI is patented till around 2027, but would you rather risk patent overlap versus a next gen, more effective drug (by Biota), or versus the chance of another competitor coming along with a better/more effective drug, I'd go with patent overlap.

Perhaps projecting forward 5-10 years and Biota won't be part of your investment strategies, but good planning goes to the heart of a well run company...the alternative is head in the sand stuff for other management and future holders to concern themselves about...